Clinical Trial Update: Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated four doses of glycopyrronium bromide (NVA237) versus the active comparator tiotropium in patients with stable COPD, with results publish…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237 (glycopyrronium bromide) (glycopyrronium bromide)
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-01-21